Anti-Human IRF8 (CT)
| Code | Size | Price |
|---|
| LEI-I-508-20ug | 20 ug | £199.00 |
Quantity:
| LEI-I-508-0.1mg | 0.1 mg | £591.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Target Species: Human
Application: Western Blot (WB)
Shipping:
Ambient
Storage:
This polyclonal antibody is stable for at least one week when stored at 2-8°C. For long term storage aliquot in working volumes without diluting and store at -20°C in a manual defrost freezer. Avoid Repeated Freeze Thaw Cycles.
Further Information
Concentration:
0.5 mg/ml
Conjugate/Tag/Label:
Purified No Carrier Protein
Format:
This polyclonal antibody is formulated in phosphate buffered saline (PBS) pH 7.4 containing 0.02% sodium azide as a preservative.
Formulation:
This polyclonal antibody is formulated in phosphate buffered saline (PBS) pH 7.4 containing 0.02% sodium azide as a preservative.
Immunogen:
PN:I-520
Long Description:
Interferons (IFN)s are involved in a multitude of immune interactions during viral infections and play a major role in both the induction and regulation of innate and adaptive antiviral mechanisms (1 for review). During infection, host-virus interactions signal downstream molecules such as transcription factors such as IFN regulatory factor-3 (IRF3) which can act to stimulate transcription of IFN-α/β genes. Unlike IRF3, IRF8 appears to act as a negative regulator of IFN-induced genes in most cases,2,3 but IRF8 mediates activation of NF-κB by the toll-like receptor 9 (TLR9) after stimulation by unmethylated CpG DNA in dendritic cells.4 Finally, it has been shown that IRF8 decreases bcl-2 expression and thus may play a role in chronic myelogenous leukemia.
Target:
IRF8
References
1. Malmgaard, L. (2004) J. Interferon & Cyto. Res. 24:439
2. Weisz, A. et al. (1992) J. Biol. Chem. 267:25589
3. Nelson, N. et al. (1993) Mol. Cell. Biol. 13:588
4. Tsujimura, H. et al. (2004) J. Immunol. 172:6820
Related Products
| Product Name | Product Code | Supplier | IRF8 Blocking Peptide | LEI-I-520 | Leinco Technologies | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|